-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Stem Cell Therapy For Epilepsy, Parkinson’S Disease And Spinocerebellar Ataxias in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Stem Cell Therapy For Epilepsy, Parkinson’S Disease And Spinocerebellar Ataxias in Parkinson's DiseaseDrug Details:Stem cell therapy...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TED-N in Paralysis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TED-N in Paralysis Drug Details:Stem cell therapy is under development for the treatment of sub-acute spinal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ensituximab in Metastatic Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ensituximab in Metastatic Pancreatic Cancer Drug Details:Ensituximab (NPC-1C, NEO-101, NEO-102) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Seliciclib in Rheumatoid Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Seliciclib in Rheumatoid Arthritis Drug Details: Seliciclib (CYC-202) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Nasopharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Nasopharyngeal Cancer Drug Details: BGBA-445 is under development for the treatment of advanced,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Melanoma Drug Details: BGBA-445 is under development for the treatment of advanced, metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Bladder Cancer Drug Details: BGBA-445 is under development for the treatment of advanced,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Renal Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Renal Cell Carcinoma Drug Details: BGBA-445 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: BGBA-445 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Non-Small Cell Lung Cancer Drug Details: BGBA-445 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Drug Details: BGBA-445 is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Solid Tumor Drug Details: BGBA-445 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Metastatic Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Metastatic Pancreatic Cancer Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Gastroesophageal (GE) Junction Carcinomas Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Melanoma Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Synovial Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Synovial Sarcoma Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Leiomyosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Leiomyosarcoma Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Hepatocellular Carcinoma Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Angiosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Angiosarcoma Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic agent. It is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.